Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 6, Pages 697-707
Publisher
Informa Healthcare
Online
2016-03-09
DOI
10.1517/13543784.2016.1162784
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel and next-generation androgen receptor–directed therapies for prostate cancer: Beyond abiraterone and enzalutamide
- (2016) Richard M. Bambury et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory
- (2015) Melina Arnold et al. EUROPEAN JOURNAL OF CANCER
- Re: Effect of Bipolar Androgen Therapy for Asymptomatic Men with Castration-resistant Prostate Cancer: Results from a Pilot Clinical Study
- (2015) Nathan Wilken et al. EUROPEAN UROLOGY
- Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
- (2015) Theodoros Karantanos et al. EUROPEAN UROLOGY
- Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer
- (2015) Daniel P. Petrylak et al. INVESTIGATIONAL NEW DRUGS
- AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies
- (2015) A. Omlin et al. INVESTIGATIONAL NEW DRUGS
- Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
- (2015) Vincent C. O. Njar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
- (2015) M. T. Schweizer et al. Science Translational Medicine
- CYP17A1 inhibitors in castration-resistant prostate cancer
- (2015) Lissette Gomez et al. STEROIDS
- Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations
- (2015) Daan Joost De Maeseneer et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Androgen receptor aberrations in the era of abiraterone and enzalutamide
- (2015) Florian Jentzmik et al. WORLD JOURNAL OF UROLOGY
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors
- (2014) Stephen W. Rafferty et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells
- (2014) Jeffrey Cummings et al. BMC CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Quo vadis: Advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies
- (2014) Won Kim et al. CANCER
- A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer
- (2014) Kazuhiro Suzuki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2014) Robert Dreicer et al. CLINICAL CANCER RESEARCH
- Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
- (2014) M. Hussain et al. CLINICAL CANCER RESEARCH
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
- (2014) P. J. Toren et al. MOLECULAR CANCER THERAPEUTICS
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer
- (2013) Robert H. Bradbury et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
- (2013) D Bianchini et al. BRITISH JOURNAL OF CANCER
- Beyond abiraterone
- (2013) Álvaro Pinto CANCER BIOLOGY & THERAPY
- Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer
- (2013) M. Shiota et al. CANCER RESEARCH
- Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
- (2013) Lina Yin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer
- (2013) Puranik Purushottamachar et al. JOURNAL OF MEDICINAL CHEMISTRY
- AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
- (2013) S. A. Loddick et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Pathogenesis and Progression of Prostate Cancer
- (2013) Randy Schrecengost et al. SEMINARS IN ONCOLOGY
- Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor
- (2013) Hui Zhu et al. Current Oncology Reports
- Resistance Emerges to Second-Generation Antiandrogens in Prostate Cancer
- (2013) W. G. Nelson et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Landmarks in hormonal therapy for prostate cancer
- (2012) Peter Hammerer et al. BJU INTERNATIONAL
- Angiogenesis in prostate cancer: onset, progression and imaging
- (2012) Giovanna Russo et al. BJU INTERNATIONAL
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Small heat shock proteins in cancer therapy and prognosis
- (2012) Amina Zoubeidi et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Reply to W.R. Robinson
- (2012) Dennis S. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Androgen insensitivity syndrome
- (2012) Ieuan A Hughes et al. LANCET
- Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer
- (2012) John T. Isaacs et al. PROSTATE
- Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
- (2011) Tomohiro Kaku et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Molecular Alterations during Progression of Prostate Cancer to Androgen Independence
- (2011) P. Saraon et al. CLINICAL CHEMISTRY
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
- (2011) Daniel C. Danila et al. EUROPEAN UROLOGY
- Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
- (2011) Y. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Molecular genetics of prostate cancer: new prospects for old challenges
- (2010) M. M. Shen et al. GENES & DEVELOPMENT
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E
- (2010) C Andrieu et al. ONCOGENE
- Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer
- (2010) Samuel R. Denmeade et al. PROSTATE
- p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer
- (2009) Sak Kudahetti et al. BJU INTERNATIONAL
- Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy
- (2009) M. P. Steinkamp et al. CANCER RESEARCH
- Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
- (2009) K. K. Waltering et al. CANCER RESEARCH
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
- (2009) Z. Guo et al. CANCER RESEARCH
- DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer
- (2009) Jason M D'Antonio et al. ENDOCRINE-RELATED CANCER
- Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
- (2009) Michael J. Morris et al. EUROPEAN UROLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of Competing Mortality in Advanced Head and Neck Cancer
- (2009) Loren K. Mell et al. JOURNAL OF CLINICAL ONCOLOGY
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started